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Acute enteric infections caused by salmonellas remain a major public health burden worldwide. Poultry,
particularly chickens, are known to be the main reservoir for this zoonotic pathogen. Although some progress
has been made in reducing Salmonella colonization of broiler chickens by using biosecurity and antimicrobials,
it still remains a considerable problem. The use of host-specific bacteriophages as a biocontrol is one possible
intervention by which Salmonella colonization could be reduced. A total of 232 Salmonella bacteriophages were
isolated from poultry farms, abattoirs, and wastewater in 2004 and 2005. Three phages exhibiting the broadest
host ranges against Salmonella enterica serotypes Enteritidis, Hadar, and Typhimurium were characterized
further by determining their morphology and lytic activity in vitro. These phages were then administered in
antacid suspension to birds experimentally colonized with specific Salmonella host strains. The first phage
reduced S. enterica serotype Enteritidis cecal colonization by >4.2 log10 CFU within 24 h compared with
controls. Administration of the second phage reduced S. enterica serotype Typhimurium by >2.19 log10 CFU
within 24 h. The third bacteriophage was ineffective at reducing S. enterica serotype Hadar colonization.
Bacteriophage resistance occurred at a frequency commensurate with the titer of phage being administered,
with larger phage titers resulting in a greater proportion of resistant salmonellas. The selection of appropriate
bacteriophages and optimization of both the timing and method of phage delivery are key factors in the
successful phage-mediated control of salmonellas in broiler chickens.
Salmonella continues to be a major public health burden world-
wide (http://www.who.int/mediacenter/factsheets/fs139/en/). More
than 35,000 cases of human salmonellosis were reported in the
United States in 2004 alone (6), and more than 192,000 cases
were reported in the European Union during the same period
(13). The annual cost of medical treatment for salmonellosis, in
addition to lost productivity, imposes a considerable financial
burden on many countries. The USDA estimated this cost at
more than $2.3 billion for the United States in 2005 (http://www
.ers.usda.gov/briefing/FoodborneDisease/features.htm). Contam-
inated poultry products are widely accepted as a major source
of Salmonella infections (7). However, controlling Salmonella
in poultry is problematic and for broiler chickens this has relied
historically on a combination of farm biosecurity and the use of
antibiotics (11). Concerns regarding the use of chemical addi-
tives in food production have led the European Union to ban
many of the antibiotics and growth promoters used in the
rearing of broiler chickens. These include spiramycin and tylo-
sin phosphate, which were banned in 1999 (4). In the United
States, the FDA has taken similar steps with the recent with-
drawal of enrofloxacin for use in poultry production (http:
//www.fda.gov/oc/antimicrobial/baytril.pdf). Banning or signif-
icantly reducing agricultural antibiotic usage may reduce
produce quality, yields, and microbiological safety (26). Like-
wise, constraints on chemical treatments such as chlorine in the
abattoir may increase the risk of contamination with bacterial
pathogens. Further, significant improvements in biosecurity on
poultry farms are likely to be very expensive and difficult to
maintain (11), so there is a need to find an acceptable, cost-
effective way of preventing infection of poultry with Salmonella
(2). Bacteriophage therapy is one possible method of achieving
this goal which has gained prominence in recent years (25, 27).
Bacteriophages (phages) are natural predators of bacteria and
are ubiquitous in the environment (21). The use of host-spe-
cific bacteriophages has been promoted as a cost-effective and
adaptable approach to control zoonotic bacteria (26). Phages
have unique advantages compared with antibiotics (17). They
replicate only on the targeted subset of bacteria, avoiding the
imbalance of commensal gut flora (dysbiosis) often caused by
broad-spectrum antibiotics. Additionally, they only replicate as
long as the targeted bacterium is present and so are naturally
self-limiting (8). Phages have been used against zoonotic
pathogens in live animals and on food surfaces in previous
studies (3, 5, 24). Bacteriophages have been used to reduce the
numbers of Campylobacter jejuni bacteria in commercial broil-
ers by up to 5.0 log10 CFU g
1 cecal content (18). However,
only modest reductions of up to 1.3 log10 CFU have been
recorded for similar studies with Salmonella enterica serotype
Enteritidis (23). Both Campylobacter and Salmonella phages
can be isolated readily from poultry excreta and the poultry
farm environment (9, 12, 14) and therefore would not intro-
duce any new biological entity into the food chain if used
therapeutically. The emergence of bacteriophage-insensitive
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mutants (BIMs) has long been perceived as a major limitation
of phage therapy (8). However, unlike chemotherapeutic
agents such as antibiotics, phages constantly evolve to circum-
vent their host’s defenses and resistant bacteria are often less
fit or less virulent than their phage-sensitive counterparts (24).
Here we describe the use of Salmonella phages to reduce the
numbers of different Salmonella serotypes colonizing the ceca
of commercial broiler chickens. We also describe the in vitro
experiments used to characterize and select suitable phage
therapy candidates. Finally, we report the incidence of phage
resistance in vivo and the implications of this for Salmonella
phage therapy in broiler chickens.
MATERIALS AND METHODS
Isolation of bacteriophage from environmental samples. Samples of poultry
excreta and effluent were taken from 26 farms, poultry-processing plants, and
wastewater treatment plants in southern England during 2004 and 2005. These
environmental samples were diluted 1:9 (wt/vol) in nutrient broth (NB, CM0001;
Oxoid, Basingstoke, United Kingdom) before the addition of 8.0 log10 CFU of
each of three Salmonella Nalr host strains (S. enterica serotypes Enteritidis
P125109, Hadar 18, and Typhimurium 4/74) and incubation at 37°C for 24 h.
Following enrichment, a 1-ml sample of each culture was subjected to centrifu-
gation at 13,000  g for 5 min. The supernatant was then filtered through a
0.45-m-pore-size membrane (16533K; Sartorius, Go¨ttingen, Germany) before
20-l volumes of filtrate were spotted onto the surfaces of Salmonella lawns
prepared by a modification of the method described by Sambrook and colleagues
(22). Briefly, this consisted of adding 0.1 ml of an 8.0-log10-CFU-ml 1 suspen-
sion of Salmonella in maximum-recovery diluent (MRD, CM0733; Oxoid) to 5 ml
of molten overlay agar (NB containing 0.5% [wt/vol] bacteriological agar LP0011
[Oxoid]), gently shaking the mixture, and adding it to prewarmed (37°C, 30 min)
nutrient agar (CM0003; Oxoid) plates containing 25 g ml sodium nalidixate1
(N4382; Sigma, Dorset, United Kingdom) and 1 g ml novobiocin1 (N1268;
Sigma). The plates were incubated at 37°C for 24 h before examination for
plaques. Individual plaques were extracted from the overlay agar with a pipette
and suspended in 100 l of SM buffer (50 mM Tris-Cl [pH 7.5], 0.1 M NaCl, 8
mM MgSO4  7H2O, 0.01% gelatin, reagents from Sigma). This suspension was
incubated for 15 min at 37°C with 100 l of an 8.0-log10 suspension of Salmonella
before addition to 5 ml of molten overlay agar and pouring onto a nutrient agar
plate. These plates were incubated as described above and examined for plaques
after 24 h. Single plaques were propagated in this way a total of three times to
ensure that the isolates represented a single clone.
Enumeration of salmonellas in cecal contents. A suspension of cecal contents
(1:9, wt/vol) was prepared in MRD and then decimally diluted in the same
medium down to 104. A 100-l volume of each dilution was spread plated onto
modified brilliant green (BG) agar, (CM0329; Oxoid) containing 25 g ml
sodium nalidixate1 and 1 g ml novobiocin1. The plates were incubated at
37°C for 24 h before typical Salmonella colonies were counted. Representative
Salmonella colonies were confirmed by slide agglutination tests with poly(O)-,
poly(H)-, and serotype-specific antisera (Pro-Lab Diagnostics, Cheshire, United
Kingdom).
Bacteriophage enumeration in cecal contents. A suspension of cecal contents
(1:9, wt/vol) was prepared in SM buffer and subjected to centrifugation at
13,000  g for 5 min to remove bulk debris. The supernatant was then filtered
through a 0.45-m-pore-size filter to remove any remaining bacteria. Decimal
dilutions of this filtrate were prepared in SM buffer down to 104 and subse-
quently spotted (20 l) onto lawns of the appropriate Salmonella host as de-
scribed above.
Host range determination. The host range of each bacteriophage isolate was
determined with 70 Salmonella isolates. The Salmonella serotypes and strains
used were Enteritidis PT4 (n  15), Enteritidis UT (n  4), Enteritidis PT21B
(n  2), Enteritidis PT1B, 4,12:d: (n  7), Enteritidis UT (n  6), Typhi-
murium PT36 (n  2), Typhimurium PT208, Typhimurium F98, Binza (n  5),
3,15:y: (n  3), Virchow (n  2), Typhi, Stanley, Ohio, Kisarowe, Hadar PT2,
Togba, Barielly, Munster/Orion, Infantis, Senftenburg, Montevideo, Kattburg,
Saint Paul, Kubacha, Amsterdam, Hadar 18, Java, Derby, Braenderup, Agama,
and Amina. Bacterial lysis was determined by spotting 20 l of a 7.0-log10-PFU-
ml1 suspension of phage onto lawns of Salmonella prepared as described above.
After allowing 20 min for the spots to be absorbed, the plates were inverted and
incubated for 24 h at 37°C before the degree of lysis was recorded.
Phage replication in vitro. A 20-ml volume of NB, prewarmed at 37°C, was
inoculated with 100 l of an overnight culture of Salmonella (approximately 109
CFU ml1). The inoculated broth was then incubated statically for 4 h at 37°C.
Following incubation, aliquots (200 l) of this broth were inoculated with dilu-
tions of phage suspension to give multiplicities of infection (MOIs) of approxi-
mately 100, 103, and 106. Three replicate aliquots of each MOI, along with
Salmonella-only controls, were then transferred to the wells of a honeycomb
microtiter plate. These plates were incubated at 37°C in a Bioscreen-C auto-
mated microbiology growth curve analysis system (Labsystems Corp., Finland).
The optical density (600 nm) of each well was recorded at 30-min intervals for
24 h. Duplicate samples of each MOI and control were used for the contempo-
raneous enumeration of Salmonella bacteria and phages in the suspension at 1-h
intervals for 10 h and again at 24 h. For enumeration of salmonellas, decimal
dilutions of each suspension were spread plated (100 l) onto BG agar in
triplicate and incubated at 37°C for 24 h before examination for Salmonella
colonies. For bacteriophage enumeration, a 1-ml aliquot of each suspension was
subjected to centrifugation at 13,000  g for 5 min. The supernatant was then
filtered through a 0.45-m-pore-size filter to remove any remaining bacteria.
Decimal dilutions of this filtrate were prepared in SM buffer and subsequently
spotted (20 l) onto lawns of the appropriate Salmonella host as described above.
Examination of phage morphology (electron microscopy). Eight microliters of
an 8.0-log10-PFU-ml1 suspension of phage was added to the surface of a
glow-discharged, carbon-coated Pioloform grid and fixed for 2 min with glutar-
aldehyde vapor. Excess sample was removed, and the grid was washed with a
drop of double-distilled water. Negative staining was performed by adding 1 drop
of 0.5% uranyl acetate to the grid surface, and excess stain was removed imme-
diately. The grids were allowed to air dry for 20 min and were then observed with
a JEOL 1220 transmission electron microscope. Digital images from the micro-
scope were captured with a SIS Megaview III camera.
Experimental birds. Salmonella-free Ross broiler chickens were obtained at 34
days of age from a commercial supplier (Lloyd Maunder, Devon, United King-
dom). The birds were housed in groups of three in floor boxes in a controlled
environment under strict conditions of biosecurity. To ensure that the experi-
mental birds remained free of naturally occurring infection, fecal samples were
taken each day and tested for Salmonella by enrichment in modified Rappaport-
Vassiliadis soya peptone broth (CM0669; Oxoid) and then streaking onto BG
agar. Fecal samples were also taken to determine if any preexisting Salmonella
phages were present by using the enrichment method described for the environ-
mental samples. Following infection, the birds were sacrificed at intervals and the
ceca were aseptically removed. The contents of the lumen were collected in
sterile universal tubes for Salmonella and phage enumeration. Salmonella colo-
nization of the livers of the birds was ascertained by inserting a swab into the liver
and using this to inoculate a BG agar plate for a semiquantitative count. The
swab was then enriched for Salmonella in modified Rappaport-Vassiliadis soya
peptone broth, followed by plating onto BG agar as described above.
Bacteriophage therapy trials. Broiler chickens (n  216 for trial 1 and 108 for
trial 2) were separated at random into one of three units. Each unit was used for
one of three Salmonella strains: Enteritidis P125109, Hadar 18, or Typhimurium
4/74. The birds in each unit were separated equally into four rooms (A, B, C, or
D) and housed in groups of three in floor boxes. The birds in each room were
treated as follows: the birds in room A were all inoculated with Salmonella only;
in room B, the birds were inoculated with phage only; and in rooms C and D, the
birds received both Salmonella and phage. All Salmonella and bacteriophage
suspensions were administered by oral gavage. At 36 days of age, the birds in
rooms A, C, and D were challenged with 1 ml of an 8.0-log10-CFU-ml1 sus-
pension of Nalr Salmonella in phosphate-buffered saline (PBS, BR0014; Oxoid);
the birds in room B were inoculated with 1 ml of PBS. At 38 days of age, the birds
in groups B, C, and D were inoculated with either 1 ml of 9.0 (trial 1) or 11.0
(trial 2) log10 PFU of bacteriophage 151 (S. enterica serotype Enteritidis
P125109), 25 (S. enterica serotype Hadar 18), or 10 (S. enterica serotype
Typhimurium 4/74) in PBS containing 30% (wt/vol) CaCO3 as an antacid. At the
same time, the birds in group A were inoculated with 1 ml of PBS containing
30% (wt/vol) CaCO3. Three animals from each room were sacrificed daily fol-
lowing phage treatment for up to 6 days (trial 1) or 3 days (trial 2). The cecum
was aseptically removed from each bird, and the contents were decimally diluted
in MRD or SM buffer for the enumeration of salmonellas and phages, respec-
tively.
Statistical treatment of data. The significance of differences between control
and phage-treated experimental groups was determined on log10-transformed
data by a single-factor analysis of variance (ANOVA; Microsoft Excel 2002). The
significance of increased phage resistance in Salmonella colonies isolated from
phage-treated birds was determined by the chi-square test (SPSS 14.0 for Mi-
crosoft Windows).
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RESULTS
Isolation and characterization of phages. A total of 232
Salmonella phages were isolated from 26 sampling sites
(broiler farms, poultry abattoirs, and wastewater plants) during
2004 and 2005. Following three rounds of serial plaque puri-
fication, the host range of each phage was determined against
70 Salmonella isolates representing 24 different serotypes (a
portion of this screening is shown in Table 1). The 232 phage
isolates could be ascribed to more than 80 lytic profiles. How-
ever, when differences between the lytic spectra of bacterio-
phage are small, further characterization is required to ensure
that the phage isolates are not identical. On the basis of the
lytic-spectrum data, three phages with the broadest host range
against S. enterica serotypes Enteritidis (151), Hadar (25),
and Typhimurium (10) were selected for further character-
ization. Examination of the phage suspensions by electron mi-
croscopy revealed that S. enterica serotype Enteritidis phage
151 belongs to the Myoviridae family of double-stranded
DNA phages. S. enterica serotype Hadar phage 25 and S.
enterica serotype Typhimurium phage 10 belong to the Sipho-
viridae family of double-stranded DNA phages. Representative
electron micrographs of these phages are presented in Fig. 1.
Replication dynamics of phage in vitro. The replication dy-
namics of each candidate phage were determined in vitro at
MOIs of 100, 103, and 106 prior to application in vivo. Both the
optical density and plate count data indicated that the number
of bacteria of each Salmonella serotype was reduced apprecia-
bly in the presence of phage at each MOI after 24 h (Fig. 2).
When the highest MOI was used, S. enterica serotype Enteri-
tidis P12509, Hadar 18, and Typhimurium 4/74 numbers were
TABLE 1. Lytic spectra of 10 Salmonella bacteriophage isolates determined on 41 Salmonella host strainsa
S. enterica serotype or strain
Lysis by bacteriophage:
10 25 27 28 36 37 51 92 104 151
3,15:y:          
4,12:d:     ()   ()  ()
Agama          
Amina          
Amsterdam , H         
Barielly          
Binza ()         
Braenderup          
Derby , H () () ()  ()  S  
Enteritidis (Harrington) (), H () () () () () () () () S
Enteritidis (Platten) (), H () () () () () , H () , H 
Enteritidis P125109 , H () () ()  () , H () , H 
Enteritidis PT1B () ()  ()  ()    
Enteritidis PT21B  ()  ()  ()    
Enteritidis PT4 ()         
Enteritidis UT () ()  ()  ()    
Hadar 18     S   S  S
Hadar PT2          
Infantis          
Java , H () () () S ()  S  
Kattburg          
Kisarowe          
Kubacha          
Montevideo          
Munster/Orion , H         
Ohio          
Saint Paul ()   () () ()    ()
Senftenburg          
Stanley          ()
Togba          
Typhi ()         
Typhimurium (Mabbott)  ()  ()  ()    
Typhimurium (Rawlings)  () () ()  () , H  , H 
Typhimurium (Turner)  ()  ()  S    
Typhimurium 4/74  () () () () ()  ()  
Typhimurium DT104          ()
Typhimurium F98  (), R () () S ()  S  ()
Typhimurium LT2 , H () () ()  ()    
Typhimurium PT208  () () () () ()  ()  S
Typhimurium PT36  ()  S, R () ()  ()  
Virchow          
Total no. of strains
lysed
24 23 19 22 18 22 7 19 7 20
a Shown is a subset of the lytic-spectrum data obtained for 232 bacteriophage isolates screened against 70 Salmonella strains. Results were recorded as follows:,
confluent lysis; , semiconfluent lysis; , individual plaques; parentheses, opalescent lysis; H, halo; R, regrowth of Salmonella; S, shadow lysis; , no lysis.
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reduced by means of 2.2, 2.5, and 5.9 log10 CFU ml
1, respec-
tively, after 24 h compared with the controls. These reductions
were significant by a single-factor ANOVA (P 0.00001). The
scale and duration of Salmonella reduction varied according to
the MOI used, with higher ratios of phage to bacteria resulting
in the greatest initial falls (10 h following infection). How-
ever, the differences between MOI groups generally became
less pronounced during the 24-h incubation period (Fig. 2).
In vivo trials. Phages 151, 25, and 10 were used at a lower
titer (9.0 log10 PFU ml
1, trial 1) and a higher titer (11.0 log10
PFU ml1, trial 2) in separate in vivo trials to reduce the numbers
of Nalr S. enterica serotype Enteritidis P125109, Hadar 18, and
Typhimurium 4/74 bacteria colonizing the ceca of broiler chick-
ens. When the phages were administered at 9.0 log10 PFU, no
significant reductions in the cecal carriage of Salmonella in the
phage-treated broilers was recorded for any of the serotypes
tested over the 6-day duration of the trial. This was despite a
significant increase in the titers of phage 151 (5.2  1.63 log10
PFU g1 cecal content compared with controls) within 24 h of
phage administration (data not shown). The phages were rapidly
removed from the chicken intestine in the absence of Salmonella
hosts (group B) and were below the limit of detection after 48 h
(151) or 72 h (10, 25). In the second trial, the chickens were
sacrificed over a period of 3 days only, as the results from trial 1
indicated that any decrease in Salmonella numbers following
phage treatment should be apparent in this period (data not
shown). The results of this second trial are presented in Fig. 3.
The higher phage titer corresponded to a significant reduction in
the mean cecal colonization by S. enterica serotypes Enteritidis
P125109 and Typhimurium 4/74 after 24 h (1.53  2.38 and
3.48  1.88 log10 CFU g
1 cecal content, respectively, compared
with the control groups [5.77  1.85 and 5.67  0.41 log10 CFU
g1 cecal content]). These reductions in cecal colonization were
significant for both S. enterica serotypes Enteritidis (P 
0.0000001) and Typhimurium (P  0.000001) by a single-factor
ANOVA. No significant differences between control and phage-
treated groups were recorded for birds colonized with S. enterica
serotype Hadar 18 (5.77  0.45 and 5.34  0.34 log10 CFU g
1
cecal content for phage-treated and control groups, respectively).
Resistance to phage in vivo. Following the phage therapy
trials, up to six Salmonella colonies were randomly selected from
spread plates from the cecal contents of control and phage-
treated birds. These colonies were used to prepare lawns onto
which phage suspensions were spotted in order to determine the
presence of BIMs. A total of 595 colonies were tested in this way
(271 for trial 1 and 324 for trial 2). For both trial 1 and trial 2,
salmonellas recovered from control animals harbored a subpopu-
lation which was naturally resistant to the phage chosen for ther-
apy. Over the course of trial 1, the number of phage-resistant
Salmonella colonies from control animals was 3/24 (12.5%) for S.
enterica serotype Enteritidis, 3/23 (13%) for S. enterica serotype
Hadar, and 3/44 (6.8%) for S. enterica serotype Typhimurium.
Corresponding values for trial 2 were 11/37 (29.7%) for S. enterica
serotype Enteritidis, 3/36 (8.3%) for S. enterica serotype Hadar,
and 1/52 (1.9%) for S. enterica serotype Typhimurium. Following
phage treatment in trial 1, the percentage of BIMs approximately
doubled (S. enterica serotype Enteritidis, 11/52 [21.2%]; S. en-
terica serotype Hadar, 9/39 [23%]; S. enterica serotype Typhi-
murium, 9/89 [10%]). The percentage of BIMs recovered from
phage-treated birds in trial 2 was greater than that in trial 1 for S.
enterica serotypes Enteritidis (65/74, 87.8%) and Typhimurium
(52/62, 83.9%) but not for serotype Hadar (5/63, 7.93%). The
increase in BIMs recovered from phage-treated birds harboring
S. enterica serotypes Enteritidis and Typhimurium in trial 2 was
significant for both groups (P  0.001) by the chi-square test.
Salmonella colonies recovered from phage-treated birds (n 20)
did not maintain their phage-resistant phenotype when subcul-
tured on BG agar five times. A small-scale trial was performed to
establish if phage resistance was maintained in vivo. Three Sal-
monellaBIMs (S. enterica serotypes Enteritidis R1, Hadar R2, and
Typhimurium R3) were selected for each serotype from trial 1
and used to reinfect a small group of birds (n  9) as described
above. After 6 days, the birds were sacrificed and the cecal con-
tents were cultured for salmonellas and phage as described above.
Colonization levels in the ceca for each resistant Salmonella did
not differ appreciably from the controls (data not shown). Addi-
tionally, when six colonies from each bird were subsequently
screened for phage resistance, the proportion of BIMs did not
differ appreciably from the controls.
DISCUSSION
Bacteriophage therapy is undergoing a renaissance in industri-
alized countries (1). An increasing number of studies have exam-
ined the use of phage against food spoilage bacteria or zoonotic
pathogens (15, 16). However, for phage therapy to be useful in
FIG. 1. Electron photomicrographs of Salmonella phages 10 (A), 25 (B), and 151 (C). Phages 10 and 25 both exhibit icosahedral heads
and flexible tails typical of members of the Siphoviridae family. With its icosahedral head and contractile tail, phage 151 typifies members of the
Myoviridae family. The bars represent 250 nm.
4546 ATTERBURY ET AL. APPL. ENVIRON. MICROBIOL.
agricultural applications, it must be tested under conditions which
emulate commercial practices. We sought to isolate and use
phage to reduce the numbers of three Salmonella serotypes in
commercially obtained animals under conditions more congruous
with the broiler farm environment. Using specific-pathogen-free
animals or applying phage in chick models of Salmonella coloni-
zation may produce misleading results as Salmonella colonizes
these animals more readily than older birds (10). Applying phage
just prior to slaughter is more likely to result in greater efficacy
and a reduced proportion of BIMs (8).
Before the three phages were used against Salmonella in
vivo, the replication dynamics of each phage-host system were
characterized in vitro. Each phage was able to significantly
reduce the numbers of their respective Salmonella hosts with
MOIs of 100, 103, and 106. In the case of 10 applied at an
MOI of 106, S. enterica serotype Typhimurium counts were
reduced to below the limit of detection over a 24-h period.
It was envisaged that phage treatment would be most effi-
cacious for Salmonella close to the slaughter age of commer-
cially reared broiler chickens (approximately 40 to 42 days in
FIG. 2. Graphs A1, B1, and C1 show the optical density readings (at 600 nm) of NB cultures of S. enterica serotypes Enteritidis P125109, Hadar
18, and Typhimurium 4/74, respectively, over a 24-h period. Phages 151, 25, and 10 were separately added to exponential growth phase cultures
of S. enterica serotypes Enteritidis, Hadar, and Typhimurium, respectively, at MOIs of 100 (E), 103 (), and 106 (). Optical density readings taken
from uninfected cultures are also shown (F). Graphs A2, B2, and C2 show the plate counts of bacteriophages (f) and uninfected (F) and infected
() Salmonella cultures recorded from the same samples (only data for the highest MOIs are presented). All means and standard deviations were
calculated by using data from six replicates (optical density) or plate counts (culture) per MOI.
VOL. 73, 2007 PHAGE REDUCTION OF SALMONELLA IN BROILER CHICKENS 4547
the United Kingdom). Therefore, the efficacy of phage therapy
would be maximized by the use of a high titer of bacteriophage
to reduce Salmonella colonization by passive inundation (19,
20). In the first trial, the birds were inoculated with 9.0 log10
PFU of phage. This should have resulted in an approximate
MOI of 106, which was found to be highly effective in vitro.
However, cecal counts of the three Salmonella serotypes were
not reduced significantly following phage treatment. The dy-
namics of phage-bacterium interactions in vivo may be very
different from those in vitro because of the viscosity of the gut
matrix (29), complex physicochemical environment, and host
defenses (8). The numbers of salmonellas in the ceca of com-
mercial broiler chickens and on processed carcasses are gen-
erally low (10, 28). This compounds the problems phage have
in locating a suitable host in a complex intestinal milieu con-
taining large numbers of “decoy” bacteria and particulate mat-
ter. The influence of these decoys may be negligible when the
number of target bacteria is high, for example, with Campy-
lobacter (	7.0 log10 CFU g
1 cecal content). However, as the
ratio of target-to-decoy bacteria decreases, the number of
phage required to achieve a significant reduction in host num-
bers increases. Indeed, if the number of target bacteria falls
below a minimum number, termed the phage proliferation
threshold (19, 30), the large number of phage required may
render phage therapy impractical.
In order to assess whether a higher phage MOI would be
more effective, a second in vivo trial was performed with 11.0
log10 PFU. It was clear from the second trial that increasing the
MOI by 100-fold overcame many of the problems of the low
number of host bacteria present in the ceca. On the first day
after phage treatment, S. enterica serotype Enteritidis bacterial
numbers were reduced significantly by 2.52 log10 CFU g
1. By
day 2, the S. enterica serotype Enteritidis count in the phage-
treated birds was 1.53 2.38 log10 CFU, compared with 5.77
1.85 log10 CFU in control birds. A significant reduction in S.
enterica serotype Typhimurium counts was also recorded for
phage-treated birds on day 2 (mean of 3.48  1.88, compared
with 5.67  0.41 log10 CFU g
1 for controls). However, no
significant reductions in S. enterica serotype Hadar counts were
recorded in either trial 1 or trial 2. This was surprising in view
of the results obtained for the other serotypes in trial 2 and the
activity recorded for 25 in vitro. The proportion of S. enterica
serotype Hadar BIMs recovered from phage-treated birds re-
mained low compared with the other two serotypes (7.9%,
compared with 87.8% for S. enterica serotype Enteritidis and
83.9% for S. enterica serotype Typhimurium). If phage therapy
relies mainly on passive inundation rather than successive
rounds of viral infection and replication, significant numbers of
phage are needed to adsorb to individual host cells. S. enterica
serotype Hadar 18 may not possess a sufficient number of
accessible receptors on the cell surface to allow the adsorption
of large numbers of phage. Loss or alteration of the phage
receptor(s) or restriction modification systems is unlikely to
explain why 25 was ineffective, as this would have been de-
tected during the in vitro experiments. Nevertheless, it is clear
that the behavior of 25 in vitro was not a reliable indication
of its activity in vivo. Identifying the receptor(s) for 25 may
allow more precise bacteriophage therapy through the use of
cocktails of phages which adsorb to different receptors. This
may also need to be the case for phages which infect S. enterica
serotypes Enteritidis and Typhimurium in order to delay the
succession of phage-resistant mutants.
This study has demonstrated that bacteriophages can be
used to significantly reduce the cecal colonization of S. enterica
serotypes Enteritidis and Typhimurium in commercial broiler
chickens. Although BIMs were able to colonize chicken ceca
within 24 to 48 h of phage treatment, phage resistance was not
maintained for long periods either in vitro or in vivo. The
results of this study are promising, although further work needs
to be undertaken to determine the optimal timing and delivery
of bacteriophage in a real-life poultry industry setting.
FIG. 3. Efficacy of high-titer phage treatment in reducing Salmo-
nella counts in the ceca of broiler chickens (trial 2). Broiler chickens
colonized by S. enterica serotype Enteritidis P125109 (A), Hadar 18
(B), or Typhimurium 4/74 (C) were treated separately with 11.0 log10
PFU of phage 151, 25, or 10, respectively. Salmonella counts from
the ceca of individual control birds (f) and phage-treated birds ()
are presented as log10 CFU g
1 cecal content.
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